Biotechasx…..
“…..AGC upfront payments are a great way tocreate value for shareholders.” 16/03/2017; SP 0.155
“Anothercheap top up @12.5” 10/07/2017; SP 0.13
“Within 2 years, RGS could be market ready in Japan. Not just Phase II, but GMP level ready.
‘[RGS]We believe that it will takeanywhere from 1.5 years to 2 years before we will have GMP level investigational product ready’” 14/08/2017; SP 0.12
“Daily fluctuations will inevitably happen, especially on days with smaller volume, but SH who follow closely RGS would know the best is yet to come andsitting tight another few weeks even couple of months will pay big dividends.” 12/07/2018; SP 0.185
“New investorsjoining now before next take-off(commercial/licensing partnership in Japan then US) are going to enjoy the rewards.” 24/07/2018; SP 0.220
“We know the Edison Research report is paid for, but still good to see theSP lifted from $0.71 to $0.87.” 05/09/2018; SP 0.150
“Solid throughout with a few gems: 1.#RGS management is clearly confident the partnership will be announced within 5 and 1/2 weeks (end of Q2), 2. RGS only the 17th Australian company tosecure a significant technology licensing agreement in Japanin past 20 years, 3.Animal Health portfolio still there and developing.Very strong performance. Exciting times ahead. 22/11/2018; SP 0.185
“And to set the record straight from the announcement, John Martin has not been "instrumental" in the creation of RGS. He joined first as a consultant in year 3, then as a Director. Only when *Dr Graham Vesey, the brains behind RGSdecided he was more comfortable as CSO than CEO, did John Martin get appointed.” 23/01/2019; SP 0.160
“Happy to wait, and I, too, nibble modestly at some of thoseshares offered at almost an all-time low.” 18/02/2019; SP 0.120
“At 7c it's a bargain. …..” 04/10/2019; SP 0.069
“CSO (former CEO and co-founder) *Dr Graham Veseyhas a strong track record in biotech commercialisation and success, his research is solid, and his#motto has always been "under promise, over deliver". ^The Board is strong, experienced with excellent skills mix.” 18/05/2020 SP 0.065
---------------------
^04/06/2020 RGS: today announced that non-executive director Dr Glen Richards has resigned to allow him to focus on his other commitments.
*(2020) “BioPoints owner Professor Graham Vesey and his experienced team continue to lead with new innovative products advancing Microbiology technology.”
#03/07/2018 [RGS] today announced it was on track to complete its clinical collaboration with a Japanese partner for Progenza in Japan in the near- term.The company had disclosed that it anticipated completing the collaboration before the end of 30 June [2018]but discussions have taken longer than originally anticipated. Part of this delay isdue to there being several interested parties in active discussions for licensing Progenza.
